An experimental pilot study on immune and inflammatory biomarkers in patients with advanced prostatecancer treated with degarelix vs. GnRH agonist and with cardiovascular disease
Latest Information Update: 19 Sep 2022
Price :
$35 *
At a glance
- Drugs Degarelix (Primary) ; Leuprorelin
- Indications Prostate cancer
- Focus Pharmacodynamics
- 18 Sep 2022 Status changed from recruiting to completed.
- 09 May 2017 New trial record